{"id":915726,"date":"2025-12-03T11:06:33","date_gmt":"2025-12-03T16:06:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\/"},"modified":"2025-12-03T11:06:33","modified_gmt":"2025-12-03T16:06:33","slug":"soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\/","title":{"rendered":"Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space"},"content":{"rendered":"
\n

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) — via BioMedWire<\/a>: \u2014 Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire<\/a> (“BMW”), one of 75+ brands within\u00a0the\u00a0Dynamic Brand Portfolio<\/a>@IBN<\/a>\u00a0(InvestorBrandNetwork<\/a>)<\/u>, a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.<\/p>\n

To view the full publication, \u201cChronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now,\u201d please visit: https:\/\/ibn.fm\/Htmsp<\/a><\/p>\n

Chronic conditions and rare diseases in the aging population present an urgent and expanding challenge within the U.S. healthcare system, especially as more than 30 million Americans are affected by rare diseases, according to the National Institutes of Health. The vast majority of these conditions lack any FDA-approved treatment, leaving older adults especially vulnerable as age-related symptoms often obscure or delay diagnosis.<\/p>\n

This rising burden has increased demand for new therapies that can address real unmet need. Soligenix Inc., a late-stage biopharmaceutical company, is developing multiple treatments for rare diseases, including HyBryte[TM] (synthetic hypericin) for cutaneous T-cell lymphoma, and is now conducting the final confirmatory clinical study required before filing for worldwide marketing approval. As the Trump administration advances new health policy initiatives affecting chronic and rare diseases, Soligenix\u2019s work sits at a critical intersection of medical innovation and national health priorities.<\/p>\n

\n About <\/b>
\n Soligenix Inc.<\/b>\n <\/p>\n

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (\u201cSGX301\u201d or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (\u201cCTCL\u201d). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (\u201cSGX302\u201d) into psoriasis, the company\u2019s first-in-class innate defense regulator (\u201cIDR\u201d) technology, dusquetide (\u201cSGX942\u201d) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (\u201cSGX945\u201d) in Beh\u00e7et\u2019s disease.<\/p>\n

The company\u2019s Public Health Solutions business segment includes development programs for RiVax(R), its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), the company\u2019s vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of Soligenix\u2019s vaccine programs incorporates the use of its proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases (\u201cNIAID\u201d), the Defense Threat Reduction Agency (\u201cDTRA\u201d) and the Biomedical Advanced Research and Development Authority (\u201cBARDA\u201d).<\/p>\n

For further information, visit the company\u2019s website at\u00a0www.Soligenix.com\u00a0<\/a>.<\/p>\n

\n NOTE TO INVESTORS:\u00a0<\/b>The latest news and updates relating to SNGX are available in the company\u2019s newsroom at\u00a0https:\/\/ibn.fm\/SNGX<\/a><\/p>\n

\n About BioMedWire<\/strong>\n <\/p>\n

\n BioMedWire<\/a>\u00a0(\u201cBMW\u201d) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the\u00a0Dynamic Brand Portfolio<\/strong><\/a>\u00a0@\u00a0IBN<\/strong><\/a>\u00a0that delivers:<\/strong>\u00a0(1) access to a vast network of wire solutions via\u00a0InvestorWire<\/a>\u00a0to efficiently and effectively reach a myriad of target markets, demographics and diverse industries;<\/strong>\u00a0(2) article and\u00a0editorial syndication to 5,000+ outlets<\/a>;<\/strong>\u00a0(3) enhanced\u00a0press release enhancement<\/a>\u00a0to ensure maximum impact;<\/strong>\u00a0(4)\u00a0social media distribution<\/a>\u00a0via IBN to millions of social media followers;<\/strong>\u00a0and (5) a full array of tailored\u00a0corporate communications solutions<\/a>. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today\u2019s market, BMW brings its clients unparalleled recognition and brand awareness.<\/p>\n

BMW is where breaking news, insightful content and actionable information converge.<\/p>\n

\n To receive SMS alerts from BioMedWire, \u201cBiotech\u201d to 888-902-4192 (U.S. Mobile Phones Only)<\/strong>
\n
For more information, please visit\u00a0https:\/\/www.BioMedWire.com<\/a><\/p>\n

\n DISCLAIMER<\/strong>:\u00a0BioMedWire (BMW)<\/strong><\/a>\u00a0is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by BMW are solely those of BMW. Readers of this Article and content agree that they cannot and will not seek to hold liable BMW for any investment decisions by their readers or subscribers. BMW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers\/analysts\/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.<\/p>\n

The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, BMW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer\u2019s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer\u2019s securities, including, but not limited to, the complete loss of your investment.<\/p>\n

\n BMW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.<\/strong>\n <\/p>\n

This release contains \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. \u201cForward-looking statements\u201d describe future expectations, plans, results, or strategies and are generally preceded by words such as \u201cmay\u201d, \u201cfuture\u201d, \u201cplan\u201d or \u201cplanned\u201d, \u201cwill\u201d or \u201cshould\u201d, \u201cexpected,\u201d \u201canticipates\u201d, \u201cdraft\u201d, \u201ceventually\u201d or \u201cprojected\u201d. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company\u2019s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements.<\/p>\n

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:\u00a0https:\/\/www.BioMedWire.com\/Disclaimer<\/a><\/p>\n

BioMedWire
Austin, Texas
www.BioMedWire.com<\/a>
512.354.7000 Office
Editor@BioMedWire.com<\/a>
BioMedWire is powered by\u00a0IBN<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) — via BioMedWire: \u2014 Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire (“BMW”), one of 75+ brands within\u00a0the\u00a0Dynamic Brand Portfolio@IBN\u00a0(InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, \u201cChronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now,\u201d please visit: https:\/\/ibn.fm\/Htmsp Chronic conditions and rare diseases in the aging population present an urgent and expanding challenge within the U.S. healthcare system, especially as more than 30 million Americans are affected by rare diseases, according to the National Institutes of Health. The vast majority of … <\/p>\n

Continue reading “Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-915726","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSoligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) — via BioMedWire: \u2014 Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire (“BMW”), one of 75+ brands within\u00a0the\u00a0Dynamic Brand Portfolio@IBN\u00a0(InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, \u201cChronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now,\u201d please visit: https:\/\/ibn.fm\/Htmsp Chronic conditions and rare diseases in the aging population present an urgent and expanding challenge within the U.S. healthcare system, especially as more than 30 million Americans are affected by rare diseases, according to the National Institutes of Health. The vast majority of … Continue reading "Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-03T16:06:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTc4MCM3MzAzMTM0IzUwMDE0NzgxMg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space\",\"datePublished\":\"2025-12-03T16:06:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\\\/\"},\"wordCount\":1249,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTc4MCM3MzAzMTM0IzUwMDE0NzgxMg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\\\/\",\"name\":\"Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTc4MCM3MzAzMTM0IzUwMDE0NzgxMg==\",\"datePublished\":\"2025-12-03T16:06:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTc4MCM3MzAzMTM0IzUwMDE0NzgxMg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NTc4MCM3MzAzMTM0IzUwMDE0NzgxMg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\/","og_locale":"en_US","og_type":"article","og_title":"Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space - Market Newsdesk","og_description":"NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) — via BioMedWire: \u2014 Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire (“BMW”), one of 75+ brands within\u00a0the\u00a0Dynamic Brand Portfolio@IBN\u00a0(InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, \u201cChronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now,\u201d please visit: https:\/\/ibn.fm\/Htmsp Chronic conditions and rare diseases in the aging population present an urgent and expanding challenge within the U.S. healthcare system, especially as more than 30 million Americans are affected by rare diseases, according to the National Institutes of Health. The vast majority of … Continue reading \"Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-03T16:06:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTc4MCM3MzAzMTM0IzUwMDE0NzgxMg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space","datePublished":"2025-12-03T16:06:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\/"},"wordCount":1249,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTc4MCM3MzAzMTM0IzUwMDE0NzgxMg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\/","name":"Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTc4MCM3MzAzMTM0IzUwMDE0NzgxMg==","datePublished":"2025-12-03T16:06:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTc4MCM3MzAzMTM0IzUwMDE0NzgxMg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NTc4MCM3MzAzMTM0IzUwMDE0NzgxMg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-innovative-platform-provides-novel-treatment-for-underserved-ctcl-space-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915726","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=915726"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915726\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=915726"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=915726"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=915726"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}